Monitlabsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Monitlab S.A. is a diagnostic laboratory specializing in therapeutic drug monitoring and measuring drug concentrations in blood to individualize dosing. The laboratory tests posaconazole, busulfan and other drugs, provides results within 48 hours, and conducts research and development projects funded by NCBR and the European Union.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-05-22. Active
56 1090 1362 0000 0001 4419 6852
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 1, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Fundacja Uniwersytetu Im. Adama Mickiewicza w Poznaniu | |
| Jan 23, 2020 | Aid for SME access to finance — aid for start-ups | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
Tenders
No recorded participation in tenders.
Public sector contracts
Monitlab is the contractor in one public sector contract, worth PLN 300.00.
| Public buyer | Value | |
|---|---|---|
| Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu | PLN 300.00 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board is independently authorised to make declarations on behalf of the company. In the case of a multi-member management board, the joint action of two members of the management board or of a member of the management board with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 199,720 | $2,701,242.57 | 100% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| TCIsp. z o.o. | $218,471.87 | tci.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| Pharmaxi Polandsp. z o.o. | $152,292.34 | pharmaxi.com.ua | ||
| Chemlabsp. z o.o. | $144,354.49 | chemlab.com.pl | ||
| Countess Laboratoriessp. z o.o. | $99,221.13 | countess.pl | ||
| AM Lab Solutionssp. z o.o. | $100,896.70 | amsolutions.pl | ||
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| ETA Innovations Research Hub Not for Profitsp. z o.o. | $49,920.43 | etainnovations.com | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-08-23 | Share capital change (14,000.00 PLN → 10,000,000.00 PLN) | |
| 2020-04-07 | Entered in the register |
FAQ
Last updated: 2026-02-17